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Abstract
Food allergy is a major public health problem in children, impacting upon the affected
individual, their families and others charged with their care, for example educational
establishments, and the food industry. In contrast to most other paediatric diseases,
there is no established cure: current management is based upon dietary avoidance and
the provision of rescue medication in the event of accidental reactions, which are
common. This strategy has significant limitations and impacts adversely on health-
related quality of life. In the last decade, research into disease-modifying treatments
for food allergy has emerged, predominantly for peanut, egg and cow’s milk. Most
studies have used the oral route (oral immunotherapy, OIT), in which increasing
amounts of allergen are given over weeks–months. OIT has proven effective to induce
immune modulation and ‘desensitization’ – that is, an increase in the amount of food
allergen that can be consumed, so long as regular (typically daily) doses are continued.
However, its ability to induce permanent tolerance once ongoing exposure has stopped
seems limited. Additionally, the short- and long-term safety of OIT is often poorly
reported, raising concerns about its implementation in routine practice. Most patients
experience allergic reactions and, although generally mild, severe reactions have
occurred. Long-term adherence is unclear, which rises concerns given the low rates of
long-term tolerance induction. Current research focuses on improving current
limitations, especially safety. Strategies include alternative routes (sublingual, epicu-
taneous), modified hypoallergenic products and adjuvants (anti-IgE, pre-/probiotics).
Biomarkers of safe/successful OIT are also under investigation.
Food allergy is a major public health issue throughout the
world, particularly in children. There is no established treat-
ment for use in routine clinical practice: management involves
avoidance of the culprit food(s) and rescue medication in the
event of accidental reactions (1). Food allergy impacts signif-
icantly on health-related quality of life (HRQoL) of both the
affected individual and their families. The last decade has seen
an increase in research into possible treatments for food
allergy.
Impact of food allergy
Food allergy is estimated to affect up to 6% of children in
Europe (2). The incidence is rising, with an 18% increase in
children in the last decade in the USA (3). Hospital admissions
due to anaphylaxis – the most severe manifestation of food
allergy – have doubled in the UK from 1.2 per 100,000
population per annum in 1992 to 2.4 in 2012 (4), especially in
children (0–14 years).
Cow’s milk, egg, peanut and tree nuts are the most
common food allergens in children (2). Variations in the
prevalence of allergy to different foods between countries may
depend on local dietary preferences (5). Whether local
consumption patterns also affect resolution of food allergies
is unknown. Peanut allergy persists into adulthood in 80% of
cases (6, 7). In contrast, around 50% of children with cow’s
milk and/or egg allergy develop tolerance within the first 5–
6 years of life (8, 9). Persistence of reactivity to the latter two
allergens is a significant concern, because individuals fre-
quently have more severe and complex allergic phenotype (8,
9). Given the high incidence of milk and egg allergy in the
general population, the absolute numbers of those with
persistent disease are significant, particularly in tertiary care
(10, 11).
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The spectrum of severity for symptoms during food-allergic
reactions is variable and includes life-threatening anaphylaxis
and even death (12). Cow’s milk and peanuts were the most
common triggers for fatal anaphylaxis in UK children between
1992 and 2012 (4). Fortunately, fatal anaphylaxis, while
unpredictable, is also very uncommon, with an incidence rate
of 1.81 per million person-years (95% CI 0.94–3.45) (12).
However, our inability to predict those most at risk of severe
reactions contributes to the widespread provision of rescue
medication (such as adrenaline auto-injectors) and anxiety
which impacts adversely on HRQoL to a greater degree than
that reported for chronic illnesses such as diabetes or idiopathic
arthritis (13, 14). The most common childhood allergens –
especially cow’s milk – are key dietary constituents providing
essential nutrients needed for growth and development. Diet-
ary elimination can therefore be challenging, especially in those
with multiple food allergies (15). Finally, food allergy is a
major public health issue, affecting the food industry with
regard to allergen risk management and mandatory allergen
labelling (16). There are further cost implications, not only for
affected families but also to the health system, with a doubling
of direct health costs compared to non-allergic individuals (17).
Limitations of current management for food allergy
Even with appropriate dietary avoidance, accidental allergic
reactions are common: up to 40% of children allergic to cow’s
milk had at least one reaction every year according to one
report (18). Strict avoidance in children is difficult, because the
most common food allergens (cow’s milk, egg or nuts) are
present in many dishes and manufactured products. Moreover,
allergen labelling can be poor and confusing, increasing the
potential for inadvertent allergen consumption (19). This is a
particular issue with precautionary allergen labelling: a UK-
based survey found 69% of cereals and 56% of confectionery
items have ‘may contain’ labelling to nuts, despite nuts not
being present as an ingredient (20); such labelling is often
ignored by consumers (21).
Many factors contribute to rescue medication often not
being used appropriately in the community when needed.
Many parents/patients – especially teenagers – do not carry
their medication at all times, find it difficult to identify
anaphylaxis symptoms or to use auto-injector effectively in
these stressful situations (22, 23). Others are frightened because
of needle-phobia or possible side effects (24). Many caregivers
do not receive any formal training on anaphylaxis management
from healthcare professionals. All of these issues may affect the
ability of staff within education establishments (e.g. schools) to
correctly identify and administer emergency medication in the
event of a reaction (25). Finally, fatal cases of food anaphylaxis
have been reported, even when adrenaline was administered
correctly in a timely manner (26, 27).
Oral immunotherapy for food allergy
Given the above, there is demand for a disease-modifying
treatment for food allergy, particularly for the most common,
ubiquitous and dangerous allergens in terms of fatal anaphy-
laxis: cow’s milk and peanut. Different strategies are under
investigation, the most common approach being oral
immunotherapy (OIT) with over 60 studies published in peer-
review journals. Results have been promising in terms of
effectiveness and positive impact on parent-assessed HRQoL.
However, significant concerns remain regarding the safety of
OIT, and its ability to induce permanent tolerance. Current
research focuses in improving these two key issues. The benefits
and pitfalls of OIT are summarized in Table 1.
Rationale and underlying immune modulation
OIT consists of giving increasing amounts of food allergen
orally over weeks or months (‘updosing phase’). Once the
target dose is reached, this amount is given on a regular basis,
usually daily (‘maintenance phase’). This results in an allergen-
specific immunomodulatory effect. A recent meta-analysis
showed a reduction in skin prick test wheal size and an
increase in specific IgG4-blocking antibodies following OIT to
cow’s milk, egg and peanut (28), with the latter possibly being a
biomarker for sustained unresponsiveness (29). A trend
towards a reduction in specific IgE levels was also detected.
The underlying immune mechanisms are not fully understood.
Exposure to low allergen doses seem to promote inducible T-
regulatory cells (CD25+ FoxP3+) in gut MALT tissue, which
reduces allergen-specific Th2 response through IL10 and TGFb
(30). Exposure to high allergen doses might induce allergen-
specific T-cell anergy or clonal deletion (31).
Effectiveness
OIT is effective in increasing the amount (or threshold) of
allergen food-allergic individuals are able to eat without
experiencing an allergic reaction, an effect termed desensitiza-
tion. A meta-analysis by Nurmatov et al. (28) reported a
significant reduction in the likelihood of reacting at a food
challenge following OIT compared to controls (Risk ratio:
0.21, 95% CI: 0.12–0.38). However, the ability of OIT to
induce permanent or sustained tolerance – once ongoing
exposure has stopped – has not, to date, been extensively
evaluated. The available published data are not encouraging.
Table 1 Benefits and pitfalls of oral immunotherapy for food allergy
Benefits Pitfalls
Ability to induce
desensitization
Limited ability to induce permanent
tolerance
Improvement in
Quality of life:
• Dietary limitations
• Social restrictions
• Emotional impact
• Anxiety
Improved nutrition
Increased risk for allergic reactions
Need for regular long-term
consumption
Need for extensive monitoring,
including long term
(resource-consuming)
Failure rate: around 10–35% due to
significant allergic reactions
Potential protection
against accidental reactions
Relatively high long-term dropout
rate
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In a randomized controlled trial (RCT) of OIT for egg and
cow’s milk allergy in 45 young children, tolerance rates were
equal (35%) in both the OIT and control group after OIT
(median duration 21 months) followed by 2 months off-OIT
(32). In a RCT of egg OIT, 75% (30/40) of children were
desensitized at 22 months, but only 27.5% (11/40) were
tolerant after stopping OIT for 4–6 weeks (33). Similar findings
have been reported for peanut OIT: one uncontrolled study
found that only 50% (12/24) of patients who had reached the
target peanut dose (4000 mg) maintain tolerance 4 weeks after
stopping OIT (34).
It seems a little incongruous that for other forms of
immunotherapy – such as subcutaneous immunotherapy
(SCIT) for aeroallergens and venom, success is generally
defined as tolerance (and not transient desensitization) after
3–5 years of active treatment – yet the same criteria are not
applied to OIT. Further research is needed to clarify whether a
longer course of OIT would increase rates of tolerance, and
whether OIT only accelerates allergy resolution in those who
would have developed natural tolerance without any interven-
tion. As it is difficult to determine for how long OIT
maintenance should be stopped to prove permanent tolerance
(most studies utilize a ‘short’ off-OIT phase of 2–8 weeks), the
term ‘sustained unresponsiveness’ is preferred instead of
tolerance (33).
Safety
The main limitation to OIT, and arguably the reason why the
international consensus is that it is not yet ready for routine
clinical practice, is the risk of allergic reactions (35). The lack
of consensus in safety reporting (in contrast to other forms of
allergen immunotherapy) makes it extremely difficult to
appraise the frequency of reactions and thus the safety of
OIT (30). Many studies focus on effectiveness and provide
limited safety data. The meta-analysis by Nurmatov et al. (28)
could identify data relating to systemic adverse reactions in
only 5 of the 21 studies included. An increased risk for local
reactions with OIT was reported (RR: 1.47; 95% CI: 1.11–
1.95), with a similar trend for systemic reactions, especially for
cow’s milk OIT (30). A previous meta-analysis assessing cow’s
milk OIT reported an increased risk with OIT for adrenaline
use (RR: 5.8; 95% CI: 1.6–21.9) and for all types of allergic
reactions, including those potentially life-threatening such as
bronchoconstriction (RR: 10; 95% CI: 2.4–41.4) or laryn-
gospasm (RR: 12.9; 95% CI: 1.7–18.6) (36).
Although these results are self-explanatory, they do not fully
show the complexity of OIT safety in terms of the frequency of
reactions, their severity, evolution over time and potential
relationship with cofactors or poor adherence to the OIT
protocol. These essential safety data are lacking in most studies
on OIT. Safety data may be provided as the proportion of
doses causing reactions, rather than the proportion of patients
experiencing a reaction. For example, if 5 individuals (in study
of 50 patients undergoing daily OIT over 6 months) experience
anaphylaxis to an OIT home dose, this at could be reported as
a rate of 10% (patients) or 0.05% of doses (9125 doses
administered over the 6 months). Furthermore, different clas-
sification systems are used to describe severity across studies,
and the indications to administer adrenaline can vary
considerably. In this context, there are major limitations to
compare safety outcomes across studies and identify optimal
OIT regimens.
On the one hand, most studies report that OIT-related
reactions are generally mild and usually tend to decrease or
resolve overtime. Probably many patients may undergo
successful OIT without major safety concerns (37–39). On
the other hand, worrying safety data are reported in many
studies: reactions occur in most patients. Studies report that
10–35% of children need to be withdrawn due to significant
and/or repeated reactions; cough, wheeze or stridor (which
can be regarded as potentially life-threatening) are not
uncommon (40–42). Near-fatal reactions have been reported
in asthmatic teenagers with poor compliance (43, 44). This
raises concerns about long-term safety, especially when
reaching adolescence, if permanent tolerance is not achieved.
Importantly, poor long-term adherence has been reported in
over 60% of cases after 3–5 years on cow’s milk and peanut
OIT (45, 46).
Impact on quality of life, nutrition and health economics
A few open studies of OIT have shown a positive impact on
children’s quality of life following successful OIT using
validated questionnaires to assess HRQoL (42, 47–49); how-
ever, in almost all cases, these assessments have been made in
the parents and not in the children themselves undergoing OIT,
despite such questionnaires being available for use in children
from age 8 years. Given the potential for participation in OIT
being influenced considerably by parents (rather than being up
to the child), it is important that the child’s perspective and
views on OIT are explored. No studies have addressed the
impact of OIT on HRQoL in the longer term, or in those
patients who fail OIT due to reactions. A recent study reported
that parents only perceived a very limited benefit from the child
undergoing egg OIT; interestingly, the improvement in
HRQoL correlated inversely with the frequency of OIT-related
reactions, suggesting that if safety is compromised, quality of
life does not improve (50).
No studies have, as yet, assessed whether successful OIT
improves nutrition by allowing the child to re-introduce foods
(such as cow’s milk) into their diet, although the impact on
nutrition may be limited given that OIT is not generally
performed in very young children. Studies on cost-effectiveness
of OIT are also lacking at this time. OIT studies to date have
focused on efficacy as the primary outcome. Whether this is the
most important outcome for patients has not been evaluated.
There is a need to involve patients and caregivers in defining
relevant outcomes for studies on treatments for food allergy.
Strategies to improve the safety of immunotherapy for
food allergy
Several approaches have been proposed to improve the safety
of OIT. These include research on using alternative routes of
exposure, modified hypoallergenic products and adjuvants for
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immunotherapy as well as on biomarkers of safe and successful
OIT to facilitate patient selection (Fig. 1).
Biomarkers of safe and successful OIT
The identification of biomarkers associated with safe (and
successful) OIT might help select suitable candidates more
likely to respond safely to OIT, and screen out those candidates
in whom OIT may lead to unnecessary risks. Although the
outcome of OIT probably depends on multiple factors, some
individual characteristics might have a predictive value. In a
recent study of cow’s milk OIT, patients who were withdrawn
due to significant reactions had IgE binding to a broader
diversity of peptides (especially to alpha-s1-casein) and at
higher intensity than those children who completed OIT
successfully (29). In a further study, children with frequent
and severe reactions to CM-OIT had different baseline
characteristics compared to those who tolerated OIT: higher
CM-specific IgE levels prior to OIT, more severe reactions to
low CM doses and more severe asthma (41). The same factors
were associated to early withdrawal on egg OIT in another
study (51), suggesting that OIT might be unsafe in those
individuals with persistent and more severe allergy to cow’s
milk and/or egg allergy. Excluding these ‘high-risk’ children
may seem reasonable, but it is these patients who have most to
benefit from OIT.
Alternative routes
Sublingual immunotherapy
Several studies have used the sublingual route for food
immunotherapy (peanut, cow0s milk, hazelnut, peach). This
approach builds on existing evidence on the efficacy and good
safety profile of sublingual immunotherapy (SLIT) for inhalant
allergens (52). Effector cells (mast cells, basophils) are scarce,
in the sublingual mucosa which reduces the risk of allergic
reactions. Conversely, antigen-presenting dendritic cells (e.g.
Langerhans cells) are abundant, which may promote the
induction of tolerogenic T-regulatory cells (53). SLIT for food
allergy mimics some of the immune changes seen with OIT.
SLIT for food allergy can result in decreased titrated skin prick
test and specific IgE levels, with associated allergen-specific
increases in IgG4 (46, 54–56). Systemic reactions are less
frequent on SLIT, although they still may occur, especially if
the allergen is ingested (54, 57). A recent meta-analysis found
SLIT was effective at inducing desensitization (28); however,
the increase in amount of food allergen that can be tolerated
following SLIT is modest and lower than that achievable with
OIT (54–57). Two studies have compared the efficacy of SLIT
vs. OIT for cow0s milk and peanut allergy, respectively. In both
cases, OIT resulted in an increase in threshold up to 10 times
that achieved with SLIT (54, 57). Whether the effect of SLIT is
sufficient to protect patients from accidental reactions is
unclear, as the median threshold following SLIT can be
relatively low: a study of peanut SLIT resulted in a median
threshold for reactivity of 371 mg of peanut protein – less than
2 peanuts (58). Effectiveness appears to improve with more
prolonged treatment for SLIT to cow’s milk (57), but similar
studies with peanut SLIT have provided conflicting results (58).
The lower doses used for SLIT (in comparison with OIT) may
contribute to its limited efficacy, but better safety profile.
Whether the dose used for SLIT can be increased to try to
improve efficacy without compromising safety requires inves-
tigation. Concentrating the SLIT extract to deliver higher
doses did not improve efficacy in one study, although given the
high dropout rate seen, these data must be interpreted with
caution (46). Finally, a recent trial in peanut-allergic children
suggested that pre-treatment with SLIT may improve the safety
of subsequent OIT (54). This approach is deserving of further
evaluation.
Epicutaneous immunotherapy
Epicutaneous immunotherapy (EPIT) involves the application
of a patch containing the food allergen to the skin. The
epidermis is poorly vascularized, which might limit the
potential for systemic reactions. In contrast, it contains high
numbers of potent antigen-presenting cells, which may allow
immune modulation and enhanced efficacy (59). Pre-clinical
data in peanut-sensitized mice demonstrated that peanut-EPIT
on intact skin decreased the clinical and allergen-specific Th2
responses, and increased local and peripheral Foxp3+ Tregs
(60). Furthermore, Tregs persisted for 8 weeks after the end of
EPIT, suggesting that EPIT might induce long-term tolerance
(61). A pilot study in 19 children with cow’s milk allergy using
EPIT for 3 months found a tendency towards an increased
cumulative dose, but this was not statistically significant. No
systemic reactions occurred; however, local eczematous skin
reactions were common (62). Larger studies with longer
duration are required to evaluate the effectiveness and safety
of EPIT for food allergy in humans, and phase I-II studies in
peanut-allergic patients are underway (Clinicaltrials.gov
NCT01170286 and NCT01197053). A further possibility is
that EPIT could be combined with other routes of
immunotherapy (OIT or SLIT), to improve safety and efficacy
or perhaps as an alternative route of providing ongoing
maintenance therapy.
Subcutaneous immunotherapy
The first trial on immunotherapy for food allergy was a RCT
performed in the 1990s in 12 peanut-allergic adults using SCIT
(aqueous peanut extract) for 1 year (63). All 6 patients on
Different routes of exposure
Hypoallergenic products 
Adjuvants
Oral 
 Sublingual 
Epicutaneous
 Rectal 
Subcutaneous  Naturally occurring: 
 egg/milk in baked foods 
 boiled peanut 
 Recombinant 
Peptides
 Anti-IgE
 Pre/probiotics
 Bacteria 
Antihistamines
 LTRA 
Figure 1 Strategies under investigation to improve the efficacy and
safety of OIT. LRTA, leukotriene receptor antagonists.
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active treatment required intramuscular adrenaline for sys-
temic reactions on more than one occasion, with anaphylaxis
occurring during both the rush and maintenance phases. While
SCIT resulted in an increase in threshold of reactivity at
DBPCFC, the authors acknowledged that SCIT using native
food allergen was unsafe. Subsequent studies have focused in
the development of hypoallergenic products to improve the
safety of SCIT.
Modified hypoallergenic molecules
The underlying rationale is to use products that have reduced
or no ability to bind specific IgE and activate mast cells and
basophils through modification of allergenic sites or epitopes.
However, their ability to interact with T cells is preserved to
allow immune modulation without triggering allergic reactions.
Such products can be found ‘naturally’ in our diets or
produced in the laboratory.
Naturally occurring hypoallergenic foods
There is now strong evidence that baked foods containing
extensively heated cow’s milk or egg in baked foods (such as
biscuits, cakes or muffins) are tolerated by approximately 70%
of children with milk or egg allergy (64–66). This is a result of
heat-induced protein structure modification and effects from a
gluten-containing food matrix (such as the formation of protein
aggregates), altering the ability of IgE to bind to mainly
conformational epitopes (as opposed to linear epitopes, which
are heat resistant) and cause effector cell activation (67–69).
Introducing baked foods containing egg/milk into the diet of
children who are otherwise allergic to the native allergen may be
a safe and simple way of accelerating natural tolerance, with
both clinical and laboratory data suggesting this is the case (70,
71). However, it is difficult to demonstrate that children who
tolerate extensively heated allergen outgrow their allergy due to
exposure to the allergen in baked foods, or whether these
individuals would outgrow their allergy through natural reso-
lution, independent of allergen consumption. Indeed, having IgE
against specific linear peptides/epitopes is associated with
clinical reactivity to baked foods, and a more persistent course
of cow’smilk and egg allergy (72, 73). This dilemma is difficult to
test in research, due to both ethical and pragmatic reasons (a
family who know their child tolerates the allergen in baked foods
is unlikely to agree to strict allergen avoidance, especially when
exposure may help ‘cure’ their child).
A novel approach to peanut desensitization is currently
being tested in a Phase 2/3 study (NCT02149719) using boiled
peanut. This has reduced allergenicity compared to raw or
roasted peanut (the latter being the usual type of peanut
consumed in western countries). Boiling appears to result in the
loss of key allergenic components (especially Ara h 1, 2 and 6)
into the cooking water (74, 75). Preliminary data suggest that
boiled peanut OIT might be a safe and effective to induce
desensitization in children with peanut allergy (75).
Engineered recombinant proteins
The introduction of point mutations into known IgE-binding
epitopes of food allergens, either through chemical modifica-
tion or site-directed mutagenesis, can be used to develop
recombinant proteins with reduced allergenicity. Hypoaller-
genic mutants of peanut, fish and apple allergens have been
generated using the latter technique (76). Wood et al. recently
published a phase 1 trial of a rectally administered suspension
of recombinant dominant peanut allergens (Ara h 1, Ara h 2
and Ara h 3), modified by amino acid substitutions at major
IgE-binding epitopes and encapsulated in heat/phenol killed
E. coli (EMP-123). Unfortunately, 5 of 10 peanut-allergic
adults required discontinuation due to significant allergic
reactions (77). It is not clear as to whether these outcomes
were affected by the route of exposure. An ongoing EU-funded
study aims to develop hypoallergenic recombinant major
allergens of fish (parvalbumin) and peach (lipid transfer
protein) to be used as active ingredients of SCIT for food
allergy (78).
Peptides
This approach uses overlapping peptides (protein fragments
10–20 amino acids long) which represent the entire sequence
of the allergenic protein. These short peptides cannot cross-
link two IgE molecules, but can interact with antigen-
presenting cells. Such approaches have been successfully used
for immunotherapy to aeroallergens (79). A peptide mixture
of Ara h 2, the major peanut allergen, has been tested in a
mouse model of peanut allergy with promising clinical and
immunological results (80). The most relevant tolerogenic
peptides need to be identified before human studies can be
considered (81).
Adjuvants
Anti-IgE therapy
Anti-IgE appears to be is a very promising therapy for IgE-
mediated allergic diseases, and probably acts by two mecha-
nisms: preventing free IgE molecule from binding to its
receptors on effector cells, and through effects on effector cells
including by downregulating the expression of the high-affinity
IgE receptor on mast cells, and decreasing basophil histamine
release (82). Evidence supporting its use in the management of
food allergy is encouraging but currently limited, as reviewed
elsewhere (83). In a double-blind placebo-controlled RCT in 84
peanut-allergic adults, four doses of anti-IgE were given at 4
weekly intervals (given its half-life of 26 days) (84). An increase
in the median threshold of reactivity from half a peanut before
treatment to 9 peanuts was observed, without the use of a
desensitization protocol. However, 25% of patients did not
respond, and no long-term data are described. Some studies
have demonstrated the great potential of anti-IgE in combina-
tion with OIT to allow both more rapid desensitization and
improved safety. Two pilot studies in children allergic to cow’s
milk (n = 11) and peanut (n = 13) have been published, using
anti-IgE from at least 8 weeks prior to OIT commencement
(85, 86). Around 80% of participants reached the target dose
after 7–11 weeks of updosing (2000 mg cow’s milk and
4000 mg peanut protein), an effect which persisted allowing
tolerance to higher doses (8000 mg) at DBPCFC 8–12 weeks
after stopping anti-IgE. Most patients experienced only mild
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allergic reactions; 2 children on peanut OIT experienced
bronchial reactions (86). During cow’s milk OIT, no bronchial,
laryngeal or cardiovascular reactions occurred (although 4
patients were given adrenaline nonetheless) (85). A more recent
study performed simultaneous OIT to multiple foods using
anti-IgE from 8 weeks prior to 8 weeks after starting OIT (87).
All children had reacted to doses <100 mg protein prior to
OIT, and all tolerated 4000 mg for each allergen by 9 months
of OIT (median time: 18 weeks). We are also aware of
anecdotal reports where anti-IgE has successfully been used
as an adjuvant in desensitization in individuals with previous
multiple episodes of anaphylaxis to LTP. Although anti-IgE
shows great promise in combination with OIT, more research is
needed to address unclear issues before it should be considered
ready for use outside the research setting. First, longer-term
effectiveness of OIT once anti-IgE is stopped requires further
investigation: there are case reports of IgE-facilitated OIT
where clinical symptoms to the allergen in question recurred
following withdrawal of anti-IgE therapy (88). Anti-IgE does
not seem to be equally effective in all patients (and this is
directly related to OIT safety); more research is needed into
understanding the reason for this, as well as into potential
biomarkers to predict individual treatment responses. Finally,
the high cost of anti-IgE therapy is likely to be prohibitive in
many countries.
Pre-/probiotics
Evidence from animal models and in vitro studies suggest that
gut microbiota modulate immune programming, promote oral
tolerance and are important inhibiting the development of the
allergic phenotype. The utility of pre-biotics (non-digestible
carbohydrates that stimulate the growth and/or activity of
beneficial colonic bacteria), probiotics (live microorganisms
that benefit the host) and/or symbiotics (a combination of
both) in the prevention and/or treatment of allergic diseases
has been addressed in different studies (89). Results from
animal models are encouraging, but in-human data are
minimal. A recent study addressed the potential of probiotics
to induce beneficial gut immune modulation in association
with peanut OIT (90). Tolerance rates after stopping OIT
were higher than in previous studies. However, definitive
conclusions cannot be drawn, because the authors did not
include a control group receiving OIT without probiotics.
Around half of the patients experienced significant allergic
reactions to OIT.
Bacteria
As bacteria are potent stimulants of Th1 immune responses,
modified bacterial products are under investigation as adju-
vants for allergen-specific immunotherapy. In a dog model of
food allergy, a single subcutaneous injection with a mixture of
heat-killed Listeria monocytogenes (HKLM) and either pea-
nut, or milk and wheat, significantly reduced anaphylactic
symptoms on oral food challenge (91). Heat/phenol killed
E. coli was associated to the above-mentioned rectal EMP-123
vaccine for peanut allergy (77).
Antihistamines and leukotriene receptor antagonists
Daily antihistamines have been used during OIT updosing in
several studies (37, 40, 92). This is expected to reduce mild oral,
skin, nasal and/or ocular symptoms related to OIT doses.
There is anecdotal evidence of the potential usefulness of
Figure 2 Current knowledge gaps
which need to be evaluated for their
impact on safety of OIT. SLIT,
sublingual immunotherapy; EoE,
eosinophilic oesophagitis.
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leukotriene receptor antagonists to treat gastrointestinal symp-
toms during OIT (93). However, the impact on these treat-
ments on OIT safety cannot be determined, as no RCTs have
been performed.
Long-term safety
There is little data relating to the longer-term safety of OIT.
Clearly, a major issue is that of sustained unresponsiveness vs.
transient desensitization, the latter requiring ongoing regular
exposure to maintain desensitization. One concern remains
issues of compliance, particularly in teenagers where this can
be a problem during OIT (43). It is not uncommon for
individuals who have undergone OIT to continue to experi-
ence aversion and/or oral symptoms to maintenance doses. It
is not difficult to foresee a scenario where an individual is not
compliant with their maintenance dosing, but believes they
are now ‘tolerant’ to the allergen in question – thus risking
the possibility of a severe reaction in the event of future
allergen exposure.
Finally, there is also a concern that OIT can result in the
development of eosinophilic oesophagitis (EoE) and other
food-induced enteropathies. A systematic review reported
EoE in up to 2.7% of patients undergoing OIT for IgE-
mediated food allergy (although the review is based on
incomplete datasets, because most trials of OIT have not
reported the presence or absence of EoE as a longer-term
adverse event) (94).
Conclusions
Disease-modifying treatments for food allergy are under
development and have shown promising results to date, in
terms of efficacy. OIT does induce desensitization, but its
ability to induce permanent tolerance once ongoing exposure
has stopped is limited. More research is needed into strategies
– such as combining routes of exposure or identifying
biomarkers of safer and successful OIT – to improve both
efficacy and safety of immunotherapy treatments for food
allergy (Fig. 2). Safety is concerning: most patients experience
reactions to OIT doses, and severe reactions have been
reported. It is for this reason that the general consensus is
that OIT is not ready for clinical practice (35). This will not be
resolved with the current heterogeneity in reporting adverse
events. Most importantly, it is time to establish an interna-
tional consensus on safety data reporting from trials of
immunotherapy for food allergy.
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